Often growth failure is part of a complex condition, which can be very rare or even unique, with the child having many other signs and symptoms. The paediatric endocrinologists’ experience and skills are key to selecting the tests and procedures that will advance diagnosis and help the child. Technology, genetics and clinical skills are increasing the number of children receiving a differential diagnosis, rather than the diagnosis of exclusion, namely, idiopathic short stature. This series of medical education activities aims to explore issues with diagnosing children with growth disorders and discuss some of the technical advances that can enhance diagnosis, including when they should be employed. Advice on which tests to use will be discussed, especially in light of the continuing development, wider availability and affordability of genetic testing.
Learning of the career path and life journey of an eminent clinician offers inspiration and insight for those less advanced in their careers. Professor Wieland Kiess, a legend and successful leader in paediatric endocrinology will be interviewed as part of this learning journey, to offer advice based on his long and successful career and broad publication history.
At the end of the blended learning journey, participants should be able to:
Clinicians, particularly paediatricians, working in growth disorder management and those in general practice; some content of interest to specialist growth disorder nurses.
The official language of this educational programme will be English. Simultaneous translation into Spanish and Korean will be provided.
The GROWTH DISORDERS 2025: CURRENT CHALLENGES, SOLUTIONS AND RECOMMENDATIONS will be submitted for CME accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) and/or the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and for Continuing Professional Development (CPD) credits.
Growth Disorders 2025: Current Challenges, Solutions and Recommendations
Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.
Justin Davies is Professor of Paediatric Endocrinology at the University of Southampton, UK. Prof Davies research interests include growth and imprinting disorders (including Silver-Russell and Temple syndrome), secondary osteoporosis and care for children with differences of sex development. He Co-Chairs the British Society of Paediatric Endocrinology and Diabetes Growth Disorders Special Interest Group, and is developing a standardised national approach to growth assessment and management of growth hormone deficiency.
He is Chair of the international – DSD care quality committee. Prof Davies is member of the national NHS England service specification working group– developing national policy to optimise paediatric endocrine services and improve care. He is a Senior Editor for Endocrine Connections. Prof Davies leads the European Society for Paediatric Endocrinology, Winter School. He is a past Chair of the British Society of Paediatric Endocrinology and Diabetes 2016-2020.
Paul Dimitri BSc, MBChB, FRCPCH, PhD is a Consultant in Paediatric Endocrinology at Sheffield Children’s NHS Foundation Trust, Professor of Child Health Technology at the University of Sheffield, and Professor of Child Health at Sheffield Hallam University. He has worked in paediatrics since 1998 and paediatric endocrinology since 2004, with clinical expertise in disorders of growth, puberty, and hormone regulation. He leads the Hypothalamic and Pituitary Tumour Service and co‑leads the Paediatric Late Effects Endocrinology service supporting childhood cancer survivors with endocrine complications. His research spans child health technology, endocrinology, and skeletal development, and he is widely published in these fields. Professor Dimitri is Director of the NIHR HealthTech Research Centre in Paediatrics and Child Health and Clinical Director of the national TITCH Network, driving innovation in child health technology. He previously directed the NIHR CYP MedTech Cooperative, the UK’s first paediatric MedTech Co‑operative, and served as NIHR National Children’s Specialty Lead from 2016–2024. He is Vice President for Science and Research at the Royal College of Paediatrics and Child Health, shaping national research policy. In 2025, he was awarded NIHR Senior Investigator status, recognising his leadership in applied child health research and his commitment to transforming healthcare for children and young people.
Richard JM Ross trained in medicine at The Royal London Hospital (1974-1979) and in Endocrinology at St Bartholomew’s Hospital, London (1983-1988). Appointed to Sheffield University in 1995 and is Emeritus Professor of Endocrinology, past Head of Section and currently theme lead for Diabetes, Endocrinology and Metabolism. Retired from clinical practice in 2021. Richard’s research and clinical interests are in pituitary and adrenal disease, transition endocrinology and the late effects of cancer. Richard was Chief Scientific Officer and Director on the Board of Diurnal Group Plc (2004-2022); overseeing its flotation in 2015 on the London Stock market (AIM) prior to its purchase by Neurocrine Biosciences in 2022. Served on the editorial boards of: Clinical Endocrinology (1996-2000), Growth & Growth Factors (1986-2006), Hormones (2004-2018), and J Clin Endocrinol Metab (2010-2014). Council member for the Society of Endocrinology (1999-2002), Editor Endocrinologist (2001-2004), Chair of CaHASE (2002-2015), member of the Bioscientifica Board (2006-2010), Society for Endocrinology Public Engagement Committee (2008-2011) and Nominations Committee (2010-2012). Executive Committee of the European Society of Endocrinology (2011-2015), Treasurer of the European Society of Endocrinology (2013-2015), The Growth Hormone Research Society Council (2011-2018), and The Pituitary Society Board of Directors (2019-). Received The Endocrine Societies “Outstanding Innovation Award” in 2021 and awarded the Clinical
Helen Storr is a Professor and Honorary Consultant in Paediatric Endocrinology at Queen Mary University London (QMUL) and Barts Health Trust, London. She completed a PhD in molecular endocrinology at the William Harvey Research Institute, Barts and the London School of Medicine funded by a Wellcome Trust Research Training Fellowship. Professor Storr was awarded the 2011 European Society for Paediatric Endocrinology (ESPE) Young Investigator Award and an NIHR Advanced Fellowship in 2019. Her clinical paediatric endocrine practice is broad with key clinical interests in disorders of growth. She leads an active programme of clinical and basic science research focusing on the recognition, diagnosis, and management of growth disorders in children. Key interests include the genetic diagnosis and molecular basis of growth disorders and growth hormone insensitivity. She is a member of the Editorial Board for the Journal of Clinical Endocrinology and Metabolism, member of the BSPED Research Group, medical advisor for the Child Growth Foundation (CGF) and Chairs the British Society For Paediatric Endocrinology and Diabetes (BSPED) Growth Disorders Special Interest Group.
A BSc (Hons) and MBA graduate from Welsh universities, Jeff joined the pharmaceutical industry in 1990. Jeff first worked for Janssen-Cilag, where he performed a number of commercial and marketing management roles.
Jeff joined Pfizer in 2002 as Senior Brand Manager in the Endocrinology Team and transitioned into a European marketing role in 2006. Jeff became European Brand Director in 2010. Jeff left Pfizer in 2016 to start his own consultancy company, JRB Consultancy Services Ltd.
Jeff has been involved with growth conditions for over 20 years, and has won numerous awards, both national and international, for his role in developing campaigns and support information and materials for families affected by growth conditions. Jeff was the European lead for the development of the first growth prediction tool, iGRO, which was sponsored by Pfizer, and has since been rolled out in more than 25 countries.
Jeff has been a trustee of the Child Growth Foundation for over two years and became their Chair in 2022.
Stay in the know with our CME updates
